menu search

GRTX / Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect

Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect
Galera Therapeutics shares plunged by almost 85% after the clinical-stage biopharmaceutical company revealed its New Drug Application for its investigational therapeutic avasopasem manganese (avasopasem) for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment was not approved by the Food and Drug Administration (FDA).  The company said that the FDA had informed it that the data from its Phase 3 ROMAN trial and supporting data from its GT-201 trial were “not sufficiently persuasive to establish substantial evidence of avasopasem's effectiveness and safety for reducing severe oral mucositis in patients with head and neck cancer. Read More
Posted: Aug 10 2023, 13:04
Author Name: Proactive Investors
Views: 092012

GRTX News  

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates

By Zacks Investment Research
August 14, 2023

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates

We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates. more_horizontal

Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect

By Proactive Investors
August 10, 2023

Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect

Galera Therapeutics shares plunged by almost 85% after the clinical-stage biopharmaceutical company revealed its New Drug Application for its investig more_horizontal

Why Is Galera Therapeutics (GRTX) Stock Down 83% Today?

By InvestorPlace
August 10, 2023

Why Is Galera Therapeutics (GRTX) Stock Down 83% Today?

Galera Therapeutics (NASDAQ: GRTX ) stock is falling hard on Thursday following a drug rejection by the FDA! In a Complete Response Letter ( CRL ), t more_horizontal

Galera shares tank after US FDA declines to approve inflammation disease drug

By Reuters
August 9, 2023

Galera shares tank after US FDA declines to approve inflammation disease drug

Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammation in patient more_horizontal

Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients

By Seeking Alpha
April 24, 2023

Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients

Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients. more_horizontal

Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation

By 24/7 Wall Street
February 21, 2023

Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation

On February 21, 2023, Piper Sandler initiated coverage of Galera Therapeutics with a Overweight recommendation. more_horizontal

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

By Seeking Alpha
March 23, 2022

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and improve the treatment outcome. more_horizontal

Galera Therapeutics Stock (GRTX): Why The Price Surged Today

By Pulse2
December 20, 2021

Galera Therapeutics Stock (GRTX): Why The Price Surged Today

The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased by 28.04% today. This is why it happened. more_horizontal


Search within

Pages Search Results: